There are three major OBJECTIVES in this application, each of which addresses pathways of hepatic lipid metabolism implicated in human disease. The first objective is to advance understanding of cell specific (hepatocyte versus stellate cell) lipid droplet composition and turnover in modulating hepatic fibrogenesis. The second objective is to understand how genetic modifiers of hepatic VLDL assembly regulate lipid droplet formation and fibrogenic signaling. The third objective is to understand how genetic modifiers of VLDL assembly and of fatty acid uptake also modify canalicular cholesterol secretion and gallstone susceptibility. The BACKGROUND to the current proposal is based on key published and preliminary findings implicating lipid droplet formation and fibrogenic signaling and also data linking pathways of VLDL assembly to gallstone susceptibility.
The AIMS of this proposal will test the following HYPOTHESES. Based on observations that germline L-Fabp deletion attenuates lipid droplet formation in both hepatocytes and stellate cells, AIM (1) will test the hypothesis that L-Fabp modulates lipid droplet formation and fibrogenesis associated with steatosis via cell specific pathways. Based on observations that germline L-Fabp deletion attenuates hepatic lipid droplet formation and steatosis in the setting of liver-specific Mttp deletion and also attenuates hepatic fibrosis associated with high trans fat fructose feeding, AIM (2) will test the hypothesis that VLDL assembly pathways modulate lipid droplet formation, FA trafficking and fibrogenic signaling.
AIM 2 will also examine iPS derived human hepatocyte like cells. Based on observations that liver-specific Mttp deletion attenuates gallstone formation in both the wild type and L-Fabp knockout background, AIM (3) will test the hypothesis that Mttp modifies canalicular cholesterol flux in addition to VLDL secretion. Based on other observations that CD36 deletion attenuates gallstone formation in both wild type and L-Fabp knockout background, AIM (3) will also test the hypothesis that CD36 modifies canalicular cholesterol secretion. Taken together, these studies address key issues in understanding the pathways that mediate progression of benign hepatic steatosis to fibrogenic liver injury, including the lipid mediators associated with lipid droplets. These studies also address key pathways in the genetic regulation of canalicular lipid transport and cholesterol gallstone susceptibility.

Public Health Relevance

Innovation and health relevance of this proposal This renewal application will examine critical pathways and genes that regulate fat metabolism in the liver and which can lead to liver fibrosis and/or cholesterol gallstones, both prevalent diseases associated with obesity and diabetes. We will use novel mouse strains and human liver-like cells to understand how specific genes that regulate the formation of fat droplets in liver cells work to decrease liver injury. Our studies wil also use novel mouse strains to understand the pathways leading to cholesterol gallstone disease.

National Institute of Health (NIH)
Research Project (R01)
Project #
Application #
Study Section
Hepatobiliary Pathophysiology Study Section (HBPP)
Program Officer
Serrano, Jose
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Washington University
Internal Medicine/Medicine
Schools of Medicine
Saint Louis
United States
Zip Code
Xie, Yan; Fung, Ho Yee Joyce; Newberry, Elizabeth P et al. (2014) Hepatic Mttp deletion reverses gallstone susceptibility in L-Fabp knockout mice. J Lipid Res 55:540-8
Olszak, Torsten; Neves, Joana F; Dowds, C Marie et al. (2014) Protective mucosal immunity mediated by epithelial CD1d and IL-10. Nature 509:497-502
Ong, Kuok Teong; Mashek, Mara T; Davidson, Nicholas O et al. (2014) Hepatic ATGL mediates PPAR-? signaling and fatty acid channeling through an L-FABP independent mechanism. J Lipid Res 55:808-15
Liang, Zhe; Xie, Yan; Dominguez, Jessica A et al. (2014) Intestine-specific deletion of microsomal triglyceride transfer protein increases mortality in aged mice. PLoS One 9:e101828
de Vries, Simone; Jeffe, Donna B; Pruitt, Sandi L et al. (2014) Patient, hospital, and geographic disparities associated with comanagement during hospitalization for colorectal cancer surgery. J Hosp Med 9:226-31
Schootman, M; Lian, M; Pruitt, S L et al. (2014) Hospital and geographic variability in two colorectal cancer surgery outcomes: complications and mortality after complications. Ann Surg Oncol 21:2659-66
Schootman, Mario; Lian, Min; Pruitt, Sandi L et al. (2014) Hospital and geographic variability in thirty-day all-cause mortality following colorectal cancer surgery. Health Serv Res 49:1145-64
Kushnir, Vladimir M; Nalbantoglu, Ilke; Watson, Rao et al. (2014) Advanced colorectal adenomas in patients under 45 years of age are mostly sporadic. Dig Dis Sci 59:2757-64
Bose, Sandip K; Kim, Hangeun; Meyer, Keith et al. (2014) Forkhead box transcription factor regulation and lipid accumulation by hepatitis C virus. J Virol 88:4195-203
Barrett, Bradley S; Guo, Kejun; Harper, Michael S et al. (2014) Reassessment of murine APOBEC1 as a retrovirus restriction factor in vivo. Virology 468-470:601-8

Showing the most recent 10 out of 86 publications